VIFOR PHARMA joins the Rare Disease Action Forum as member

22 Jul, 2020

We are proud to welcome Vifor Pharma as the newest member of the Rare Disease Action Forum. We look forward to Vifor’s contribution to the collaborative efforts at the RDAF multi-stakeholder platform which consists of members from industry, patient organizations, healthcare professionals, and research organizations. Together we will continue our efforts to diagnosis, treatment and care for patients with rare diseases in Switzerland.

Joint statement on the KVV/OAMal and KLV/OPAS revision

The RDAF co-signed a joint statement with other stakeholders on the revision of the Health Insurance Ordinance (KVV/OAMal) and Health Benefits Ordinance (KLV/OPAS). The statement highlights the potential negative impacts of the revision, including the following: -...

The Rare Disease Action Forum (RDAF) advocates for a fair and rapid access to high-quality treatment for patients with rare diseases in Switzerland.

In line with this concern, the RDAF would like to draw attention to the fact that the planned revision of the Health Insurance Ordinance (KVV), contrary to its stated objective, threatens patients’ access to treatment. Read our media release here.